National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 15482-15483 [2020-05630]

Download as PDF 15482 Federal Register / Vol. 85, No. 53 / Wednesday, March 18, 2020 / Notices (section 201(dd) of the FD&C Act (21 U.S.C. 321(dd)). Any application by Mr. Edwards for special termination of debarment under section 306(d)(4) of the FD&C Act should be identified with Docket No. FDA–2019–N–4046 and sent to the Dockets Management Staff (see ADDRESSES). All such submissions are to be filed in four copies (21 CFR 10.20(a)). The public availability of information in these submissions is governed by 21 CFR 10.20. Publicly available submissions may be seen in the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. Dated: March 12, 2020. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2020–05582 Filed 3–17–20; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Promoting the Rule of Law Through Improved Agency Guidance Documents Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: The Department of Health and Human Services has received an extension to the deadline to comply with Executive Order 13891: Promoting the Rule of Law Through Improved Agency Guidance Documents. Executive Order 13891, through Subsections (a) and (b), requires the establishment of a new guidance portal and the rescission of any guidance documents that are not included in it, respectively. The Office of Management and Budget (OMB), through its implementing memorandum (https://www.whitehouse.gov/wpcontent/uploads/2019/10/M-20-02Guidance-Memo.pdf), has determined the deadlines for these subsections to be February 28, 2020. OMB granted the Department of Health and Human Services an extension for subsections (a) and (b) on February 27, 2020. The Department will establish its guidance portal by August 31, 2020. A full copy of the extension letter can be found on the HHS website at, https:// www.hhs.gov/regulations/. FOR FURTHER INFORMATION CONTACT: Samuel Shipley, Office of the Executive Secretary, at Guidance@hhs.gov or (202) 690–5627. jbell on DSKJLSW7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:54 Mar 17, 2020 Jkt 250001 Dated: March 12, 2020. Ann C. Agnew, Executive Secretary, Department of Health and Human Services. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2020–05647 Filed 3–17–20; 8:45 am] Center for Scientific Review; Amended Notice of Meeting BILLING CODE 4150–03–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; R13 Conference Grants. Date: April 14, 2020. Time: 8:30 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: NIH/NHLBI, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20814 (Virtual Meeting). Contact Person: Michael P. Reilly, Ph.D., Scientific Review Officer, Office of Scientific Review, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD 20892, 301– 827–7975, reillymp@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: March 13, 2020. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–05626 Filed 3–17–20; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00070 Fmt 4703 Sfmt 4703 National Institutes of Health Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, Fellowships: Physiology and Pathobiology of the Vascular and Hematological Systems, March 27, 2020 8:00 a.m. to March 27, 2020, 8:00 p.m., The William F. Bolger Center, 9600 Newbridge Drive, Potomac, MD 20854, which was published in the Federal Register on March 4, 2020, 85 FR 12799. The meeting location is being held at the National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. The meeting date and time remains the same. The meeting is closed to the public. Dated: March 13, 2020. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–05637 Filed 3–17–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel HHS–NIH–CDC–SBIR 2018– 1 Phase II Topic 053: Effective Targeted Delivery of RNA-based Vaccines and Therapeutics. Date: April 15, 2020. Time: 2:00 p.m. to 5:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institute of Allergy and Infectious Diseases, National Institutes of E:\FR\FM\18MRN1.SGM 18MRN1 Federal Register / Vol. 85, No. 53 / Wednesday, March 18, 2020 / Notices Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Inka I Sastalla, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20852, (301) 761–6431, inka.sastalla@ nih.gov. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; HHS–NIH–CDC SBIR PHS 2018–1 Phase II Topic 052: High-Throughput Assay Platform for Quantifying Latent HIV Reservoirs. Date: April 21, 2020. Time: 2:00 p.m. to 5:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Inka I Sastalla, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20852, (301) 761–6431, inka.sastalla@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: March 13, 2020. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health jbell on DSKJLSW7X2PROD with NOTICES National Institute of Allergy and Infectious Diseases: Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. 18:54 Mar 17, 2020 Jkt 250001 Dated: March 12, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–05627 Filed 3–17–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, March 26, 2020, 8:00 a.m. to March 27, 2020, 7:00 p.m., Marriott Bethesda North Hotel & Conference Hotel, 5701 Marinelli Rd., Rockville, MD 20850 which was published in the Federal Register on January 30, 2020, 85 FR 5459. This meeting notice is amended to change the meeting location, times, and format. The meeting will now be held on March 26, 2020, 8:00 a.m. to March 27, 2020, 4:00 p.m. as a teleconference at National Cancer Institute (NCI) Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850. The meeting is closed to the public. Dated: March 13, 2020. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–05641 Filed 3–17–20; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Alcohol Abuse and Alcoholism; Amended Notice of Meeting [FR Doc. 2020–05630 Filed 3–17–20; 8:45 am] VerDate Sep<11>2014 Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed). Date: April 21, 2020. Time: 11:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G53 Rockville, MD 20852 (Telephone Conference Call). Contact Person: Konrad Krzewski, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G53, Rockville, MD 20852, 240–747–7526, konrad.krzewski@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) 15483 Notice is hereby given of a change in the meeting of the National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel, April 24, 2020, 8:00 a.m. to 5:00 p.m., National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Bethesda, MD 20817, which was published in the Federal Register on January 27, 2020, 85 FR 4673. This meeting notice is amended to change the meeting dates, times, and format. The meeting will now be held as a teleconference on two days—April 23, 2020, 8:00 a.m. to April 24, 2020, 6:00 p.m. The meeting is closed to the public. Dated: March 13, 2020. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–05645 Filed 3–17–20; 8:45 am] National Institutes of Health National Heart, Lung, and Blood Institute; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Heart, Lung, and Blood Institute Special Emphasis Panel, March 24, 2020, 08:00 a.m. to 05:00 p.m., Embassy Suites at Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015 which was published in the Federal Register on January 29, 2020, 85 FR 5221. The NHLBI Special Emphasis Panel meeting is being amended due to a change in the meeting format. This oneday meeting to be held on March 24, 2020 will be a teleconference meeting. The meeting is closed to the public. Dated: March 13, 2020. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–05625 Filed 3–17–20; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4140–01–P PO 00000 Frm 00071 Fmt 4703 Sfmt 9990 E:\FR\FM\18MRN1.SGM 18MRN1

Agencies

[Federal Register Volume 85, Number 53 (Wednesday, March 18, 2020)]
[Notices]
[Pages 15482-15483]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-05630]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel HHS-NIH-CDC-SBIR 2018-1 Phase II 
Topic 053: Effective Targeted Delivery of RNA-based Vaccines and 
Therapeutics.
    Date: April 15, 2020.
    Time: 2:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of

[[Page 15483]]

Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20892 (Telephone 
Conference Call).
    Contact Person: Inka I Sastalla, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G22, 
Rockville, MD 20852, (301) 761-6431, [email protected].

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; HHS-NIH-CDC SBIR PHS 2018-1 Phase 
II Topic 052: High-Throughput Assay Platform for Quantifying Latent 
HIV Reservoirs.
    Date: April 21, 2020.
    Time: 2:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G22, 
Rockville, MD 20892 (Telephone Conference Call).
    Contact Person: Inka I Sastalla, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G22, 
Rockville, MD 20852, (301) 761-6431, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: March 13, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-05630 Filed 3-17-20; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.